Joerg Herrmann MDProfessor of Medicine, Mayo Graduate School of Medicine, Rochester, Minnesota
Dr. Joerg Herrmann received his medical training at Ruhr University, Bochum, Germany, and completed his internship in internal medicine at the University Clinic in Essen. Following a postdoctoral research fellowship, he pursued the clinician–investigator track in internal medicine-cardiology, and further training in interventional cardiology at the Mayo Clinic, Rochester, Minnesota. He then joined the staff of the Department of Cardiovascular Diseases at the Mayo Clinic, Rochester. Currently he is an Associate Professor of Medicine at the Mayo Graduate School of Medicine and serves as the director of the Cardio-Oncology Clinic and the research director of the Ischemic Heart Disease program.
Dr. Herrmann has been receiving NIH research funding, serves as a reviewer for over 30 journals, including all major cardiovascular journals. He is also a contributor to Braunwald’s Heart Disease, the associated editor of Trends in Cardiovascular Medicine, and is the editor of the textbook Clinical Cardio-Oncology.
His main research interests are cardio-oncology, cardiac biomarkers, periprocedural myocardial infarction, atherosclerosis, and vascular biology.
Dr. Joerg Herrmann participated in the 2014 and 2016 Ponatinib in CML Cardio-Oncology Advisory Board meeting organized by ARIAD Pharmaceuticals, the 2016 Carfilzomib Advisory Board meeting organized by Amgen and is a member of the Institute for Cardio-Oncology advisory panel sponsored by Bristol-Myers Squib.
Recent Contributions to PracticeUpdate:
- Impact of Early Revascularization on MACE in Relation to Automatically Quantified Ischemia
- Strain-Guided Management of Potentially Cardiotoxic Cancer Therapy
- 2020 Top Stories in Cardiology: Dexamethasone in Hospitalized Patients With Covid-19—The RECOVERY Trial
- Myocardial Bridge Associated With Life-Threatening Ventricular Arrhythmias in Patients With an ICD
- Nonculprit Lesion Severity and Outcome of Revascularization in Patients With STEMI and Multivessel Coronary Disease
- 10-Year Outcomes From a Randomized Trial of Polymer-Free vs Durable Polymer Drug-Eluting Coronary Stents
- New Cardiac Abnormalities Following Radiation Therapy in Breast Cancer Patients Treated With Trastuzumab
- PCI vs CABG in the Treatment of Unprotected Left Main Stenosis
- AMI Treatment and Outcomes in 6.5 Million Patients With a Current or Historical Diagnosis of Cancer
- 2019 Top Stories in Cardiology: Time for Shortcuts After PCI?